Evidence map›Paper›PMID 38158300›Full record

ArticleVaccine2024

Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection.

Albert To, Teri Ann S Wong, Aquena H Ball, Michael M Lieberman, Jake Yalley-Ogunro, Mehtap Cabus, Sara Nezami, Fabian Paz, Hanne Andersen Elyard, Viktoriya Borisevich and 7 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Albert ToDepartment of Tropical Medicine, Medical Microbiology, and Pharmacology, John A. Burns School of Medicine, University of Hawai'i at Mānoa, Honolulu, HI 96813, USA.
Teri Ann S WongDepartment of Tropical Medicine, Medical Microbiology, and Pharmacology, John A. Burns School of Medicine, University of Hawai'i at Mānoa, Honolulu, HI 96813, USA.
Aquena H BallDepartment of Tropical Medicine, Medical Microbiology, and Pharmacology, John A. Burns School of Medicine, University of Hawai'i at Mānoa, Honolulu, HI 96813, USA.
Michael M LiebermanDepartment of Tropical Medicine, Medical Microbiology, and Pharmacology, John A. Burns School of Medicine, University of Hawai'i at Mānoa, Honolulu, HI 96813, USA.
Jake Yalley-OgunroBioqual Inc., Rockville, MD 20850, USA.
Mehtap CabusBioqual Inc., Rockville, MD 20850, USA.
Sara NezamiBioqual Inc., Rockville, MD 20850, USA.
Fabian PazBioqual Inc., Rockville, MD 20850, USA.
Hanne Andersen ElyardBioqual Inc., Rockville, MD 20850, USA.
Viktoriya BorisevichDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77550, USA; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77550, USA.
Krystle N AgansDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77550, USA; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77550, USA.
Daniel J DeerDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77550, USA; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77550, USA.
Courtney WoolseyDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77550, USA; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77550, USA.
Robert W CrossDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77550, USA; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77550, USA.
Thomas W GeisbertDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77550, USA; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77550, USA.
Oreola DoniniSoligenix, Inc., Princeton, NJ 08540, USA.
Axel T LehrerDepartment of Tropical Medicine, Medical Microbiology, and Pharmacology, John A. Burns School of Medicine, University of Hawai'i at Mānoa, Honolulu, HI 96813, USA. Electronic address: lehrer@hawaii.edu.
The University of Texas Medical Branch at Galveston · USBioqual · USUniversity of Hawaiʻi at Mānoa · USSoligenix (United States) · US

Funding

Regulatory Compliance Core - Galveston National Laboratory BSL4 OperationsUC7AI094660 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Dennis A Bente · 2011 to 2026
$208.8M
Preclinical Development of a Thermostable Trivalent Filovirus VaccineR01AI132323 · NIAID · UNIVERSITY OF HAWAII AT MANOA · PI LEHRER, AXEL T · 2017 to 2021
$6.3M
Pacific Center for Emerging Infectious Diseases ResearchP20GM103516 · NIGMS · UNIVERSITY OF HAWAII AT MANOA · PI YANAGIHARA, RICHARD · 2012 to 2014
$6.1M
NIAID NIH HHS R01 AI132323NIAID NIH HHS UC7 AI094660NIGMS NIH HHS P20 GM103516
6 · The paper itself

Abstract

Although two vaccines for Zaire ebolavirus (EBOV) have been licensed and deployed successfully to combat recurring outbreaks of Ebolavirus Disease in West Africa, there are no vaccines for two other highly pathogenic members of the Filoviridae, Sudan ebolavirus (SUDV) and Marburg marburgvirus (MARV). The results described herein document the immunogenicity and protective efficacy in cynomolgus macaques of a single-vial, thermostabilized (lyophilized) monovalent (SUDV) and bivalent (SUDV & MARV) protein vaccines consisting of recombinant glycoproteins (GP) formulated with a clinical-grade oil-in-water nanoemulsion adjuvant (CoVaccine HT™). Lyophilized formulations of the vaccines were reconstituted with Water for Injection and used to immunize groups of cynomolgus macaques before challenge with a lethal dose of a human SUDV or MARV isolate. Sera collected after each of the three immunizations showed near maximal GP-binding IgG concentrations starting as early as the second dose. Most importantly, the vaccine candidates (monovalent or bivalent) provided 100% protection against severe and lethal filovirus disease after either SUDV or MARV infection. Although mild, subclinical infection was observed in a few macaques, all vaccinated animals remained healthy and survived the filovirus challenge. These results demonstrate the value that thermostabilized protein vaccines could provide for addressing an important gap in preparedness for future filovirus outbreaks.

Indexed as

EbolavirusHemorrhagic Fever, EbolaMarburgvirusViral VaccinesAnimalsAntibodies, ViralHumansMacaca fascicularisSudanVaccines, CombinedWaterAntibodies, ViralVaccines, CombinedViral VaccinesWaterCoVaccine HTCynomolgus macaquesMarburg virusRecombinant protein subunitSudan ebolavirusThermostabilized vaccine

Identifiers

PMID38158300
PMCPMC10872277
OpenAlexW4390323007

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.